Singular Genomics Systems Stock Price, News & Analysis (NASDAQ:OMIC) $0.42 +0.03 (+7.75%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$0.39▼$0.4250-Day Range$0.33▼$0.5852-Week Range$0.31▼$3.00Volume173,016 shsAverage Volume1.50 million shsMarket Capitalization$30.60 millionP/E RatioN/ADividend YieldN/APrice Target$1.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Singular Genomics Systems MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside139.8% Upside$1.00 Price TargetShort InterestHealthy3.68% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 2 Articles This WeekInsider TradingAcquiring Shares$103,822 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.46) to ($1.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector327th out of 951 stocksAnalytical Instruments Industry13th out of 29 stocks 3.0 Analyst's Opinion Consensus RatingSingular Genomics Systems has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.00, Singular Genomics Systems has a forecasted upside of 139.8% from its current price of $0.42.Amount of Analyst CoverageSingular Genomics Systems has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.68% of the float of Singular Genomics Systems has been sold short.Short Interest Ratio / Days to CoverSingular Genomics Systems has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Singular Genomics Systems has recently increased by 40.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSingular Genomics Systems does not currently pay a dividend.Dividend GrowthSingular Genomics Systems does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OMIC. Previous Next 3.0 News and Social Media Coverage News SentimentSingular Genomics Systems has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Singular Genomics Systems this week, compared to 0 articles on an average week.Search Interest1 people have searched for OMIC on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Singular Genomics Systems to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Singular Genomics Systems insiders have bought more of their company's stock than they have sold. Specifically, they have bought $103,822.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders21.90% of the stock of Singular Genomics Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.75% of the stock of Singular Genomics Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Singular Genomics Systems are expected to decrease in the coming year, from ($1.46) to ($1.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Singular Genomics Systems is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Singular Genomics Systems is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSingular Genomics Systems has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Singular Genomics Systems Stock (NASDAQ:OMIC)Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.Read More OMIC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OMIC Stock News HeadlinesNovember 21, 2023 | finance.yahoo.comSingular Genomics Systems Founder Acquires 4.6% More StockNovember 16, 2023 | markets.businessinsider.comHold Rating on Singular Genomics Systems (OMIC) Amid Q3 Underperformance and Strategy ShiftDecember 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 16, 2023 | finanznachrichten.deSingular Genomics Systems, Inc.: Singular Genomics Reports Recent Highlights and Third Quarter 2023 Financial ResultsNovember 14, 2023 | benzinga.comRecap: Singular Genomics Sys Q3 EarningsNovember 14, 2023 | seekingalpha.comOMIC Singular Genomics Systems, Inc.November 4, 2023 | morningstar.comSingular Genomics Systems Inc OMICOctober 24, 2023 | finance.yahoo.comSingular Genomics to Report Third Quarter 2023 Financial Results on November 14, 2023December 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.September 28, 2023 | finance.yahoo.comBeware! 3 Biotech Stocks Waving Massive Red Flags Right NowSeptember 8, 2023 | finance.yahoo.comSingular Genomics to Present at the Gilmartin Group Emerging Growth Company ShowcaseAugust 11, 2023 | finanznachrichten.deSingular Genomics Systems, Inc.: Singular Genomics Reports Recent Highlights and Second Quarter 2023 Financial ResultsAugust 10, 2023 | msn.comGoldman Sachs Maintains Singular Genomics Systems (OMIC) Neutral RecommendationAugust 9, 2023 | msn.comSingular Genomics Systems GAAP EPS of -$0.35, revenue of $0.5MAugust 8, 2023 | finance.yahoo.comSingular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of DirectorsJuly 27, 2023 | finance.yahoo.comSingular Genomics to Report Second Quarter 2023 Financial Results on August 9, 2023June 1, 2023 | finance.yahoo.comSingular Genomics to Present at the Goldman Sachs Global Healthcare ConferenceMay 11, 2023 | msn.comSingular Genomics Systems GAAP EPS of $0.33 beats by $0.69, revenue of $0.86M misses by $0.38MMay 10, 2023 | finanznachrichten.deSingular Genomics Systems, Inc.: Singular Genomics Reports Recent Highlights and First Quarter 2023 Financial ResultsMay 10, 2023 | finance.yahoo.comQ1 2023 Singular Genomics Systems Inc Earnings CallMay 10, 2023 | msn.comSingular Genomics Sys's Earnings OutlookMay 9, 2023 | msn.comRecap: Singular Genomics Sys Q1 EarningsMay 7, 2023 | benzinga.comSingular Genomics Sys Stock (NASDAQ:OMIC), Guidance and ForecastMay 6, 2023 | benzinga.comSingular Genomics Sys Stock (NASDAQ:OMIC), DividendsMay 4, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and InMode (INMD)March 6, 2023 | finance.yahoo.comSingular Genomics Systems, Inc. (NASDAQ:OMIC) Q4 2022 Earnings Call TranscriptMarch 3, 2023 | finance.yahoo.comQ4 2022 Singular Genomics Systems Inc Earnings CallSee More Headlines Receive OMIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Singular Genomics Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today12/02/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OMIC CUSIPN/A CIK1850906 Websingulargenomics.com Phone858-333-7830FaxN/AEmployees269Year FoundedN/APrice Target and Rating Average Stock Price Target$1.00 High Stock Price Target$1.00 Low Stock Price Target$1.00 Potential Upside/Downside+139.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-90,880,000.00 Net Margins-3,571.18% Pretax Margin-3,571.18% Return on Equity-40.38% Return on Assets-30.84% Debt Debt-to-Equity Ratio0.05 Current Ratio13.64 Quick Ratio12.77 Sales & Book Value Annual Sales$760,000.00 Price / Sales40.27 Cash FlowN/A Price / Cash FlowN/A Book Value$2.71 per share Price / Book0.15Miscellaneous Outstanding Shares73,390,000Free Float57,314,000Market Cap$30.60 million OptionableNot Optionable Beta1.19 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Andrew Spaventa (Age 38)Founder, CEO, President & Chairperson of the Board Comp: $685.93kDr. David L. Barker Ph.D. (Age 81)Founder, Member of Scientific Advisory Board & Independent Director Comp: $63.75kDr. Eli N. Glezer Ph.D. (Age 54)Founder, Chief Scientific Officer & Chair of Scientific Advisory Board Comp: $496.5kMr. Dalen Meeter (Age 45)Chief Financial Officer Comp: $434.39kJyotsna GhaiChief Operating OfficerMr. Jorge Velarde Jr. (Age 56)MBA, Senior Vice President of Corporate Development & Strategy Mr. Jeff BullardHead of SalesMr. Vincent Brancaccio (Age 40)Head of Human Resources Mr. Samuel Ropp Ph.D. (Age 49)Chief Commercial Officer More ExecutivesKey CompetitorsTalis BiomedicalNASDAQ:TLISCue HealthNASDAQ:HLTHTelesis BioNASDAQ:DNAYPrecipioNASDAQ:PRPORapid Micro BiosystemsNASDAQ:RPIDView All CompetitorsInsiders & InstitutionsJacobs Levy Equity Management Inc.Bought 153,093 shares on 11/17/2023Ownership: 0.489%Eli N GlezerBought 200,000 shares on 11/16/2023Total: $86,000.00 ($0.43/share)Andrew SpaventaBought 43,468 shares on 11/16/2023Total: $17,821.88 ($0.41/share)Deerfield Management Company L.P. Series CSold 1,466,000 shares on 11/14/2023Ownership: 6.816%QVIDTVM Management LLCBought 1,188,377 shares on 11/13/2023Ownership: 1.625%View All Insider TransactionsView All Institutional Transactions OMIC Stock Analysis - Frequently Asked Questions Should I buy or sell Singular Genomics Systems stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Singular Genomics Systems in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OMIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMIC, but not buy additional shares or sell existing shares. View OMIC analyst ratings or view top-rated stocks. What is Singular Genomics Systems' stock price target for 2024? 1 analysts have issued 1 year price objectives for Singular Genomics Systems' stock. Their OMIC share price targets range from $1.00 to $1.00. On average, they predict the company's stock price to reach $1.00 in the next year. This suggests a possible upside of 139.8% from the stock's current price. View analysts price targets for OMIC or view top-rated stocks among Wall Street analysts. How have OMIC shares performed in 2023? Singular Genomics Systems' stock was trading at $2.01 at the beginning of the year. Since then, OMIC shares have decreased by 79.3% and is now trading at $0.4170. View the best growth stocks for 2023 here. Are investors shorting Singular Genomics Systems? Singular Genomics Systems saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,540,000 shares, an increase of 40.0% from the October 31st total of 1,100,000 shares. Based on an average daily trading volume, of 600,400 shares, the short-interest ratio is currently 2.6 days. Approximately 3.7% of the company's stock are sold short. View Singular Genomics Systems' Short Interest. When is Singular Genomics Systems' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024. View our OMIC earnings forecast. How were Singular Genomics Systems' earnings last quarter? Singular Genomics Systems, Inc. (NASDAQ:OMIC) announced its earnings results on Tuesday, November, 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.01. Singular Genomics Systems had a negative net margin of 3,571.18% and a negative trailing twelve-month return on equity of 40.38%. When did Singular Genomics Systems IPO? (OMIC) raised $178 million in an IPO on Thursday, May 27th 2021. The company issued 8,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen and UBS Investment Bank acted as the underwriters for the IPO. Who are Singular Genomics Systems' major shareholders? Singular Genomics Systems' stock is owned by many different retail and institutional investors. Top institutional shareholders include Deerfield Management Company L.P. Series C (6.82%), UBS Group AG (3.02%), QVIDTVM Management LLC (1.63%), Acuitas Investments LLC (0.71%), Platinum Investment Management Ltd. (0.58%) and Jacobs Levy Equity Management Inc. (0.49%). Insiders that own company stock include Andrew Spaventa, Eli N Glezer, James E Flynn, Kim P Kamdar, Michael J Pellini and Sheryl L Conley. View institutional ownership trends. How do I buy shares of Singular Genomics Systems? Shares of OMIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:OMIC) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Singular Genomics Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.